| Category Name | Content |
| Name | Hyaluronidase (Hyaluronidase Injection, Recombinant or Bovine-derived) |
| Uses | FDA-approved for enhancing the absorption and dispersion of injectable drugs. Off-label use includes dissolving hyaluronic acid fillers in cases of overcorrection, nodules, or vascular occlusion. |
| Route of Administration | Subcutaneous or intradermal injection. |
| Frequency of Use | As needed based on clinical judgment; reassess patient response before additional doses. |
| Concentration(s) | Available in vials of 150 IU/mL to 300 IU/mL. |
| Maximum Dosage | Max 1,500 IU per session. Dosing depends on the extent of hyaluronic acid filler requiring dissolution. |
| Contraindications | • Pregnancy, breastfeeding, or planning pregnancy. • Allergy to hyaluronidase or bovine proteins (if non-recombinant product is used). • Active infection, inflammation, or open wounds at the injection site. • History of severe allergic reactions or anaphylaxis. • Hypersensitivity to bee venom (cross-reactivity potential). |
| Possible Side Effects | • Common: Swelling, bruising, tenderness, redness at injection sites. • Rare: Allergic reaction, hypersensitivity, unintended filler dissolution in adjacent areas. • Severe: Anaphylaxis, severe edema, excessive soft tissue breakdown. |
| Compatibility With Other Treatments/Drugs | • Safe with: Hyaluronic acid fillers (for correction purposes). • Avoid with: Immediate post-filler injections unless treating vascular occlusion. |
| Allergies | Patients allergic to hyaluronidase or bovine proteins should not receive treatment. Conduct patch testing if history of allergic reactions. |
| Administration Time | Injection procedure takes approximately 10–20 minutes, with visible results in 24–48 hours. |
| Dosing/Settings | • Typical starting dose: 30–75 IU per 1.0 mL of hyaluronic acid filler to be dissolved. • For vascular occlusion: 150–300 IU immediately, with repeat dosing if necessary. |
| IM/Push (if applicable) | Not applicable; should only be administered subcutaneously or intradermally. |
| What To Do If Adverse Reaction Occurs | • Anaphylaxis: Administer epinephrine (0.3 mg IM), call 911, provide airway support. • Severe edema or unexpected tissue breakdown: Stop injections, apply cool compress, consider antihistamine or corticosteroid therapy. • Vascular occlusion treatment failure: Administer additional doses at 60-minute intervals if necessary, escalate to a specialist if no improvement. |
| Additional Documentation Requirements | • Signed informed consent form. • Pre-treatment photos (frontal and side views). • Documentation of past filler treatments, location, and type of filler used. • Allergy history review, including bee venom hypersensitivity screening. |